Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
2233 S Martin Luther King Dr Chicago, IL 60616 Join Healio | HemOnc Today as we celebrate the risk-takers and groundbreakers at this prestigious awards…
Vincent Law H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Vincent Law, Colin Snyder, Zhihua Chen, Pawel Kalinski, Brian J. Czerniecki, Peter A.…
What does smoking do to the lungs? Tobacco addiction expert Dr. Maher Karam-Hage, weighs in.
At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, Moffitt Cancer Center’s faculty will once again share their innovative research.
Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the…
Find out more about our events planned at ASCO, the Elsevier’s Oncology Journal Network, and browse our special conference article collection.
The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a…
Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.
Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.